

COVID-19 Vaccine

Quick Reference Guide for Healthcare Professionals



The table below provides basic information on the proper storage, preparation, and administration of the currently authorized COVID-19 vaccine products in the United States. For additional information and detailed clinical guidance go to the manufacturer's and CDC's webpages listed.

		D6-roy Modown			
		Pfizer	Moderna	Janssen	
G E N E R A L	EUA	www.fda.gov/emergency- preparedness-and-response/ coronavirus-disease-2019-covid-19/ pfizer-biontech-covid-19-vaccine	www.fda.gov/emergency- preparedness-and-response/ coronavirus-disease-2019-covid-19/ moderna-covid-19-vaccine	www.fda.gov/emergency- preparedness-and-response/ coronavirus-disease-2019- covid-19/janssen-covid-19-vaccine	
	CDC Vaccine Information	www.cdc.gov/vaccines/covid-19/ info-by-product/pfizer/index.html	www.cdc.gov/vaccines/covid-19/ info-by-product/moderna/index. html	www.cdc.gov/vaccines/ covid-19/info-by-product/ janssen/index.html	
	Manufacturer Contact information	Website: www.cvdvaccine.com	NAT-1	Marie de la companya de la contraction de la con	
		Medical information: 800-438-1985	Website: www.modernatx.com Medical Information: 866-663-3762	Website: www.vaxcheck.jnj. Medical information: 1-800-565-4008	
		Customer service: 800-879-3477		1-800-303-4008	
STORAGE & HANDLING	How supplied	Multidose vial: 6 doses	Multidose vial: 10 doses	Multidose vial: 5 doses	
	Diluent	0.9% sodium chloride (preservative-free, normal saline) provided in the ancillary kit. Do NOT use other diluent.	None	None	
	Storage Temperatures: Before Puncture	Between: -80°C and -60°C (-112°F and -76°F) until the expiration date -25°C and -15°C (-13°F and 5°F) for up to 2 weeks 2°C and 8°C (36°F and 46°F) for up to 120 hours (5 days)	Between: -25°C and -15°C (-13°F and 5°F) until the expiration date 2°C and 8°C (36°F and 46°F) for up to 30 days	Between: 2°C and 8°C (36°F and 46°F) until the expiration date.	
	Storage Temperatures: After puncture	Between: 2°C to 25°C (36°F to 77°F) for up to 6 hours. Discard any unused vaccine after 6 hours.	Between: 2°C and 25°C [36°F and 77°F] for up to 6 hours. Discard any unused vaccine after 6 hours.	Between: 2°C and 8°C (36°F and 46°F) for up to 6 hours. 9°C and 25°C (47°F and 77°F) for up to 2 hours. Discard any unused vaccine after these time frames.	
	Transport Temperatures: Before Puncture	Between: -80°C and -60°C (-112°F and -76°F) -25°C and -15°C (-13°F and 5°F) 2°C and 8°C (36°F and 46°F)	Between: -25°C and -15°C (-13°F and 5°F) 2°C and 8°C (36°F and 46°F) for up to 12 cumulative hours.	Between: 2°C and 8°C (36°F and 46°F)	
	After Puncture	Between: 2°C to 25°C (36°F to 77°F) for up to 6 hours.	Between: 2°C and 25°C (36°F and 77°F) for up to 6 hours.	Between: 2°C and 8°C (65°F and 46°F) for up to 6 hours	
	Type of Vaccine	mRNA	mRNA	Viral vector	
	Age Indications	16 years of age and older	18 years of age and older	18 years of age and older	
	Schedule	2-doses, separated by 21 days. Both doses must be Pfizer- BioNTech vaccine	2 doses, separated by 28 days. Both doses should be Moderna vaccine	1 dose only	
	Dosage	0.3 mL	0.5 mL	0.5 mL	
	Needle gauge/length	22–25 gauge, 1 – 1½"	22–25 gauge, 1 – 1½"	22–25 gauge, 1 – 1½"	

03/23/2021 CS321629-U



COVID-19 Vaccine

Quick Reference Guide for Healthcare Professionals



		Pfizer	Moderna	Janssen	
VACCINE ADMINISTRATION	Route	Intramuscular (IM) injection	Intramuscular (IM) injection	Intramuscular (IM) injection	
	Site	Deltoid	Deltoid	Deltoid	
	Thawing Frozen Vaccine	Between: 2°C and 8°C (36°F and 46°F) or Room temperature up to 25°C (77°F) Do NOT refreeze thawed vaccine.	Between: 2°C and 8°C (36°F and 46°F) or 8°C to 25°C (46°F to 77°F) Do NOT refreeze thawed vaccine.	N/A	
	Mixing Vaccine	Mix vaccine with 1.8 mL of 0.9% sodium chloride (preservative-free, normal saline)	Do NOT mix with any diluent	Do NOT mix with any diluent	
	Contraindications/ Precautions	Contraindications *Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine *Immediate allergic reaction† of any severity to a previous dose or known (diagnosed) allergy to a component of the vaccine Note: Persons who have a contraindication to an mRNA COVID-19 vaccine (Moderna or Pfizer-BioNTech) may be able to receive the Janssen COVID-19 vaccine (see footnote).* Persons who have a contraindication to Janssen COVID-19 vaccine may be able to receive an mRNA COVID-19 vaccine (see footnote).* Precautions *History of an immediate allergic reaction† to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies) *This includes people with a reaction to a vaccine or injectable therapy that contains multiple components, one of which is a vaccine component, but for whom it is unknown which component elicited the immediate allergic reaction. *People with a contraindication to mRNA COVID-19 vaccines have a precaution to Janssen COVID-19 Vaccine, and vice versa. (see footnote).* *Moderate to severe acute illness See Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html			
	Post-Vaccination Observation	30 minutes: Persons with a history of an immediate allergic reaction of any severity to any other vaccine or injectable therapy or a history of anaphylaxis (from any cause) 15 minutes: All other persons			
	Most common adverse events	Injection site: pain, swelling, redness Systemic: fatigue, headache, muscle pain, chills, fever, joint pain	Injection site: pain, swelling, redness Systemic: fatigue, headache, muscle pain, chills, fever, nausea, joint pain	Injection site: pain, redness, swelling Systemic: fatigue, headache, muscle pain, nausea, fever	

[†]For the purpose of this guidance, an immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms, such as urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within 4 hours following exposure to a vaccine or medication.

[±]Consider consultation with an allergist-immunologist to help determine if the patient can safely receive vaccination. Healthcare providers and health departments may also request a consultation from the Clinical Immunization Safety Assessment COVID vax Project https://www.cdc.gov/vaccinesafety/ensuringsafety/monitoring/cisa/index.html. Vaccination of these individuals should only be done in an appropriate setting under the supervision of a healthcare provider experienced in the management of severe allergic reactions.

03/23/2021 CS321629-U **2**

[•] People with a contraindication to mRNA COVID-19 vaccines (including due to a known PEG allergy) have a precaution to Janssen COVID-19 vaccination. People who have previously received an mRNA COVID-19 vaccine dose but have a contraindication to a second dose should wait at least 28 days to receive Janssen COVID-19 vaccine.

[•] People with a contraindication to Janssen COVID-19 vaccine (including due to a known polysorbate allergy) have a precaution to mRNA COVID-19 vaccination.